Pingyangmycin sclerotherapy for early-stage peripheral arteriovenous malformations
10.3760/cma.j.issn.1009-4598.2018.05.004
- VernacularTitle: 平阳霉素硬化治疗早期外周动静脉畸形
- Author:
Xiangjie WU
1
;
Xiafang WU
;
Chunfen LUO
;
Saike MAO
;
Shengmiao LI
;
Linjun YU
Author Information
1. Department of Pediatric Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical College, Taizhou 317000, China
- Publication Type:Clinical Trail
- Keywords:
Pingyangmycin;
Sclerosing agent injection therapy;
Arteriovenous malformations
- From:
Chinese Journal of Plastic Surgery
2018;34(5):343-347
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety and efficacy of pingyangmycin (bleomycin A5) sclerotherapy for early peripheral arteriovenous malformations (AVM).
Methods:Thirteen cases of early-stage [Schobinger clinical stage (Ⅰ/Ⅱ)] peripheral AVM patients (11 stage Ⅰ and 2 stage Ⅱ patients) aged between 3 months and 51 years were selected between January 2012 and May 2015. Pingyangmycin sclerotherapy injections were administered with B-scan ultrasonography or digital subtraction angiography positioning. All patients underwent relevant supplementary examinations before and after the procedure, and clinical evaluation was performed based on the improvement of the clinical symptoms of the patient and re-examination of lesion by imaging.
Results:A total of 88 injections were administered to the 13 patients with an average of 6.7 injections per patient, 3-6 years of follow-up. Based on clinical evaluation, 7 patients were generally cured, 3 patients had significant improvement, 2 patients had partial improvement, and 1 patient had no improvement. Seven patients had different levels of postoperative swelling that resolved on its own. No serious complications occurred.
Conclusions:Pingyangmycin sclerotherapy for treatment of early peripheral AVM was effective and had few complications. It can control further progression of pathological changes.
